A detailed history of Nuveen Asset Management, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,506,170 shares of NUVB stock, worth $3.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,506,170
Previous 875,362 72.06%
Holding current value
$3.52 Million
Previous $3.19 Million 38.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$2.58 - $3.69 $1.63 Million - $2.33 Million
630,808 Added 72.06%
1,506,170 $4.4 Million
Q1 2024

May 13, 2024

BUY
$1.46 - $3.97 $681,338 - $1.85 Million
466,670 Added 114.19%
875,362 $3.19 Million
Q4 2023

Feb 14, 2024

SELL
$0.96 - $1.53 $313,643 - $499,869
-326,712 Reduced 44.43%
408,692 $617,000
Q3 2023

Nov 14, 2023

SELL
$1.26 - $2.1 $4,997 - $8,328
-3,966 Reduced 0.54%
735,404 $985,000
Q2 2023

Aug 14, 2023

SELL
$1.56 - $1.84 $84,034 - $99,117
-53,868 Reduced 6.79%
739,370 $1.33 Million
Q1 2023

May 15, 2023

BUY
$1.6 - $2.48 $451,310 - $699,531
282,069 Added 55.18%
793,238 $1.32 Million
Q4 2022

Feb 14, 2023

SELL
$1.68 - $2.5 $107,572 - $160,077
-64,031 Reduced 11.13%
511,169 $981,000
Q3 2022

Nov 14, 2022

SELL
$0.29 - $4.04 $3,622 - $50,467
-12,492 Reduced 2.13%
575,200 $1.29 Million
Q2 2022

Aug 15, 2022

BUY
$3.24 - $5.85 $30,676 - $55,387
9,468 Added 1.64%
587,692 $1.9 Million
Q1 2022

May 16, 2022

SELL
$4.6 - $8.83 $712,471 - $1.37 Million
-154,885 Reduced 21.13%
578,224 $3.05 Million
Q4 2021

Feb 14, 2022

BUY
$7.75 - $10.05 $2.39 Million - $3.09 Million
307,748 Added 72.35%
733,109 $6.23 Million
Q3 2021

Nov 12, 2021

BUY
$7.78 - $10.0 $1.36 Million - $1.74 Million
174,318 Added 69.44%
425,361 $4.23 Million
Q2 2021

Aug 16, 2021

BUY
$9.22 - $14.48 $2.31 Million - $3.64 Million
251,043 New
251,043 $2.34 Million

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $508M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.